PLAQUE PSORIASIS

This study tests a new medicine called ORKA-001 for adults with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly patches. About 160 participants will receive either the drug or a placebo to see if it can completely clear the skin by week 16. The goal is to…

This study is testing the long-term safety and effectiveness of a drug called ORKA-001 for people with moderate-to-severe plaque psoriasis. It is an open-label extension, meaning everyone gets the drug, and it includes 240 adults who already completed a previous trial with ORKA-0…

This study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will track changes in quality of life, including skin symptoms and daily impacts, over up to 2.5 years. The goal is to see how well the drug…

This study tests a daily pill called deucravacitinib in teenagers aged 12 to 18 with moderate to severe plaque psoriasis. About 366 participants will receive either the drug or a placebo. The main goals are to see if the drug improves skin clearance by at least 75% and reduces ov…

This phase 3 trial tests whether zasocitinib, an oral medication, can safely and effectively treat moderate-to-severe plaque psoriasis in children and teens aged 4 to 17. The study involves 110 participants and lasts up to 4 years. In the first part, some receive the drug and oth…

This study tests the long-term safety of deucravacitinib compared to ustekinumab in about 3,040 adults with moderate-to-severe plaque psoriasis who also have heart risk factors like smoking, high blood pressure, or diabetes. Participants will receive one of the two medications an…

This study tests a drug called deucravacitinib in children and teens aged 4 to 18 with moderate to severe plaque psoriasis. The trial will measure how the drug works in the body, how well it clears psoriasis, and its safety over up to 5 years. Participants are randomly assigned t…

This Phase 3 trial is testing whether a new drug called QL2106 works as well as the approved medication Tremfya for people with moderate to severe plaque psoriasis. About 318 participants will receive either QL2106 or Tremfya injections over several months. The main goal is to se…

This Phase 3 trial tests D-2570, a new daily pill, in 477 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive D-2570, an active comparator (BMS-986165), or a placebo. The study measures how well the drug clears skin and improves quality …

This phase 2 trial tests an experimental oral drug called ICP-332 against a placebo in 172 adults with moderate-to-severe plaque psoriasis. Participants take the drug or placebo daily for 12 weeks. The main goal is to see if at least 75% of skin symptoms improve. If it works, ICP…

This study tests an experimental drug called D-2570 against a placebo in 390 adults with moderate to severe plaque psoriasis. The main goal is to see if the drug can clear at least 90% of skin plaques after 16 weeks of treatment. Participants must have stable psoriasis for at lea…

This study tests an experimental oral drug called a TYK2 inhibitor for people with moderate to severe plaque psoriasis. About 140 adults will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75%.

This study tests an experimental capsule called CS32582 in adults with moderate-to-severe plaque psoriasis. The trial has two parts: a short 4-week dose-finding phase and a longer 12-week phase to see how well the drug clears skin and whether it is safe. About 220 participants wi…

This Canadian study tests whether adding two questions about morning stiffness and lower back pain to a standard screening tool (PEST) can help dermatologists identify psoriatic arthritis earlier in people with moderate-to-severe plaque psoriasis. About 502 adults who are candida…

This study tests a new medicine called ORKA-002 for adults with moderate-to-severe plaque psoriasis. About 160 participants will receive either the drug or a placebo to see if it clears skin and is safe. The goal is to find the best dose and check for side effects over 16 weeks.

This study tests whether adding daily oral vitamin D3 to a standard steroid cream can improve mild to moderate psoriasis. About 24 adults will use the cream for 4 weeks, then be split into two groups: one gets vitamin D, the other a placebo, for 12 weeks. After that, everyone rec…

This early-stage study tests a new tablet called UA026 to see if it is safe and how the body processes it. It involves 124 people, including healthy volunteers and those with moderate to severe plaque psoriasis. The study is split into four parts to check different doses and the …

This study looks at the bacteria living on the skin of people with cutaneous T cell lymphoma, a rare type of skin cancer. Researchers will compare these bacteria to those on healthy people and people with other skin conditions like psoriasis. The goal is to understand if certain …

This study collects skin samples from 500 people with conditions like acne, eczema, and psoriasis, as well as healthy volunteers. Researchers will analyze the samples to find biomarkers and gene patterns linked to inflammation. The goal is to better understand these skin diseases…